

Global Urokinase Market Growth 2026-2032

<https://marketpublishers.com/r/GA3E41A3642EN.html>

Date: January 2026

Pages: 90

Price: US\$ 3,660.00 (Single User License)

ID: GA3E41A3642EN

Abstracts

The global Urokinase market size is predicted to grow from US\$ 80.30 million in 2025 to US\$ 119 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

Urokinase is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body's own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the "mesh" that holds a blood clot together. This is why urokinase is called a thrombolytic or "clot-buster." The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings.

A practical market definition should also include how urokinase is made, because that affects supply, regulatory burden, and cost. Urokinase products can differ by source. The U.S. Kinlytic label describes production from human neonatal kidney cells grown in tissue culture, and it explains extensive donor screening and virus testing/inactivation steps because it is derived from human source material. In contrast, some European product information describes urokinase that is extracted from human urine. These differences matter commercially: biologic sourcing and validation requirements make it harder for many manufacturers to enter, and they increase the importance of quality systems, change control, and reliable supply chains.

On the demand side, the most basic driver is that blood clots are common, and a subset of them are severe enough that rapid clot removal is lifesaving or limb-saving. The U.S. CDC says up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, and VTE is linked to tens of thousands of deaths.

Globally, cardiovascular diseases are still the leading cause of death, and they overlap with clot problems and high-risk hospital populations. These facts do not mean every clot patient needs urokinase. Most patients receive anticoagulants and supportive care, not thrombolytics. But they explain why hospitals continue to need a set of clot-management tools, including thrombolytic drugs, for the most urgent cases.

In 2025, global Urokinase production reached approximately 2736 BIU, with an average global market price of around US\$ 30 per MIU. The global single-line production capacity ranges from 100 to 150 BIU per year. The industry's gross profit margin is approximately 25%-35%.

One of the clearest growth “pockets” for urokinase is catheter and access-device management. Modern medicine uses a large volume of central venous catheters for chemotherapy, nutrition, antibiotics, and dialysis. These devices can become blocked by thrombus or fibrin sheaths. In Europe, regulatory summaries describe urokinase use for clots in catheters or cannulae, which is essentially “catheter clearance.” Clinical literature on thrombolytic therapy for catheter occlusion discusses multiple agents and reports that thrombolytics can restore patency in a meaningful share of blocked catheters, with performance differences by drug and dosing strategy; this is a major reason hospitals keep thrombolytic protocols for catheter salvage. When catheter salvage works, it avoids line replacement, reduces procedure risk, and helps preserve access sites—especially important for dialysis and oncology patients. This clinical logic is also why companies publicly frame catheter clearance as an attractive commercial segment when they talk about bringing urokinase products back to market.

A second demand segment is catheter-directed thrombolysis (CDT) for limb-threatening peripheral arterial occlusion or extensive venous thrombosis, where drug is infused locally through a catheter rather than given as a full systemic infusion. Product information for urokinase in Europe explicitly describes acute peripheral arterial occlusions and notes that catheter-directed local lysis is the preferred method of administration for that scenario. More recent reviews also describe CDT as an effective endovascular method for thrombotic peripheral artery occlusions, while emphasizing the need for careful monitoring because bleeding and other complications are real. This creates a steady, procedure-linked demand for urokinase (and competing thrombolytics) in hospitals that perform vascular interventions. The market driver here is not only disease incidence; it is the expansion of interventional capability, better imaging, and more hospitals building vascular teams that can do “minimally invasive” clot removal rather than open surgery in selected patients.

At the same time, a major market trend is that urokinase is not the only clot-buster, and in some very large indications it has been replaced by other approaches. In acute ischemic stroke, for example, many regions use alteplase or tenecteplase, and mechanical thrombectomy has grown for large-vessel occlusions. In myocardial infarction, primary PCI has replaced thrombolysis in many systems where rapid catheterization is available. These shifts matter because they move thrombolytic use toward more specialized niches. In catheter clearance specifically, alteplase has strong clinical adoption in many settings, and reviews discuss its clearance rates and how other agents compare. So, one trend in the urokinase market is “narrower but deeper”: fewer broad, mass-market indications, but ongoing need in hospital procedures and device-related clots where protocols and economics favor certain agents.

Global key players of urokinase include Syner-Med, LIVZON, Wanhua Biochem, etc. The top three players hold a share about 50%.

LP Information, Inc. (LPI) ' newest research report, the “Urokinase Industry Forecast” looks at past sales and reviews total world Urokinase sales in 2025, providing a comprehensive analysis by region and market sector of projected Urokinase sales for 2026 through 2032. With Urokinase sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Urokinase industry.

This Insight Report provides a comprehensive analysis of the global Urokinase landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urokinase portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Urokinase market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urokinase and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urokinase.

This report presents a comprehensive overview, market shares, and growth opportunities of Urokinase market by product type, application, key manufacturers and

key regions and countries.

Segmentation by Type:

Urokinase Powder

Urokinase Solution

Segmentation by Clinical Use:

Pulmonary Embolism Thrombolysis

Deep Vein Thrombosis

Peripheral Arterial Occlusion Thrombolysis

Catheter / Cannula Occlusion Clearance

Others

Segmentation by Administration Approach:

Systemic Infusion

Catheter-directed Thrombolysis (CDT)

Intracatheter Dwell / Lock Technique

Segmentation by Purity:

Standard Clinical Grade

High-purity / Low-impurity Grade

Low Endotoxin / Low Bioburden Specifications

Segmentation by Application:

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Syner-Med

Wanhua Biochem

Jiangxi Haoran Bio-Pharma

Jiangsu Aidea Pharmaceutical

Techpool

Microbic Biosystems

LIVZON

Wuhan Humanwell Pharma

Tianjin Biochem Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Urokinase market?

What factors are driving Urokinase market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Urokinase market opportunities vary by end market size?

How does Urokinase break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Urokinase Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Urokinase by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Urokinase by Country/Region, 2021, 2025 & 2032
- 2.2 Urokinase Segment by Type
 - 2.2.1 Urokinase Powder
 - 2.2.2 Urokinase Solution
 - 2.2.3 Urokinase Sales by Type
 - 2.2.3.1 Global Urokinase Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Urokinase Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Urokinase Sale Price by Type (2021-2026)
- 2.3 Urokinase Segment by Clinical Use
 - 2.3.1 Pulmonary Embolism Thrombolysis
 - 2.3.2 Deep Vein Thrombosis
 - 2.3.3 Peripheral Arterial Occlusion Thrombolysis
 - 2.3.4 Catheter / Cannula Occlusion Clearance
 - 2.3.5 Others
 - 2.3.6 Urokinase Sales by Clinical Use
 - 2.3.6.1 Global Urokinase Sales Market Share by Clinical Use (2021-2026)
 - 2.3.6.2 Global Urokinase Revenue and Market Share by Clinical Use (2021-2026)
 - 2.3.6.3 Global Urokinase Sale Price by Clinical Use (2021-2026)
- 2.4 Urokinase Segment by Administration Approach

2.4.1 Systemic Infusion

2.4.2 Catheter-directed Thrombolysis (CDT)

2.4.3 Intracatheter Dwell / Lock Technique

2.4.4 Urokinase Sales by Administration Approach

2.4.4.1 Global Urokinase Sales Market Share by Administration Approach (2021-2026)

2.4.4.2 Global Urokinase Revenue and Market Share by Administration Approach (2021-2026)

2.4.4.3 Global Urokinase Sale Price by Administration Approach (2021-2026)

2.5 Urokinase Segment by Purity

2.5.1 Standard Clinical Grade

2.5.2 High-purity / Low-impurity Grade

2.5.3 Low Endotoxin / Low Bioburden Specifications

2.5.4 Urokinase Sales by Purity

2.5.4.1 Global Urokinase Sales Market Share by Purity (2021-2026)

2.5.4.2 Global Urokinase Revenue and Market Share by Purity (2021-2026)

2.5.4.3 Global Urokinase Sale Price by Purity (2021-2026)

2.6 Urokinase Segment by Application

2.6.1 Hospital

2.6.2 Clinic

2.6.3 Others

2.6.4 Urokinase Sales by Application

2.6.4.1 Global Urokinase Sale Market Share by Application (2021-2026)

2.6.4.2 Global Urokinase Revenue and Market Share by Application (2021-2026)

2.6.4.3 Global Urokinase Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Urokinase Breakdown Data by Company

3.1.1 Global Urokinase Annual Sales by Company (2021-2026)

3.1.2 Global Urokinase Sales Market Share by Company (2021-2026)

3.2 Global Urokinase Annual Revenue by Company (2021-2026)

3.2.1 Global Urokinase Revenue by Company (2021-2026)

3.2.2 Global Urokinase Revenue Market Share by Company (2021-2026)

3.3 Global Urokinase Sale Price by Company

3.4 Key Manufacturers Urokinase Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Urokinase Product Location Distribution

3.4.2 Players Urokinase Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR UROKINASE BY GEOGRAPHIC REGION

4.1 World Historic Urokinase Market Size by Geographic Region (2021-2026)

4.1.1 Global Urokinase Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Urokinase Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Urokinase Market Size by Country/Region (2021-2026)

4.2.1 Global Urokinase Annual Sales by Country/Region (2021-2026)

4.2.2 Global Urokinase Annual Revenue by Country/Region (2021-2026)

4.3 Americas Urokinase Sales Growth

4.4 APAC Urokinase Sales Growth

4.5 Europe Urokinase Sales Growth

4.6 Middle East & Africa Urokinase Sales Growth

5 AMERICAS

5.1 Americas Urokinase Sales by Country

5.1.1 Americas Urokinase Sales by Country (2021-2026)

5.1.2 Americas Urokinase Revenue by Country (2021-2026)

5.2 Americas Urokinase Sales by Type (2021-2026)

5.3 Americas Urokinase Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Urokinase Sales by Region

6.1.1 APAC Urokinase Sales by Region (2021-2026)

6.1.2 APAC Urokinase Revenue by Region (2021-2026)

6.2 APAC Urokinase Sales by Type (2021-2026)

6.3 APAC Urokinase Sales by Application (2021-2026)

6.4 China

- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Urokinase by Country
 - 7.1.1 Europe Urokinase Sales by Country (2021-2026)
 - 7.1.2 Europe Urokinase Revenue by Country (2021-2026)
- 7.2 Europe Urokinase Sales by Type (2021-2026)
- 7.3 Europe Urokinase Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Urokinase by Country
 - 8.1.1 Middle East & Africa Urokinase Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Urokinase Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Urokinase Sales by Type (2021-2026)
- 8.3 Middle East & Africa Urokinase Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Urokinase
- 10.3 Manufacturing Process Analysis of Urokinase
- 10.4 Industry Chain Structure of Urokinase

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Urokinase Distributors
- 11.3 Urokinase Customer

12 WORLD FORECAST REVIEW FOR UROKINASE BY GEOGRAPHIC REGION

- 12.1 Global Urokinase Market Size Forecast by Region
 - 12.1.1 Global Urokinase Forecast by Region (2027-2032)
 - 12.1.2 Global Urokinase Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Urokinase Forecast by Type (2027-2032)
- 12.7 Global Urokinase Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 Syner-Med
 - 13.1.1 Syner-Med Company Information
 - 13.1.2 Syner-Med Urokinase Product Portfolios and Specifications
 - 13.1.3 Syner-Med Urokinase Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 Syner-Med Main Business Overview
 - 13.1.5 Syner-Med Latest Developments
- 13.2 Wanhua Biochem
 - 13.2.1 Wanhua Biochem Company Information
 - 13.2.2 Wanhua Biochem Urokinase Product Portfolios and Specifications
 - 13.2.3 Wanhua Biochem Urokinase Sales, Revenue, Price and Gross Margin

(2021-2026)

13.2.4 Wanhua Biochem Main Business Overview

13.2.5 Wanhua Biochem Latest Developments

13.3 Jiangxi Haoran Bio-Pharma

13.3.1 Jiangxi Haoran Bio-Pharma Company Information

13.3.2 Jiangxi Haoran Bio-Pharma Urokinase Product Portfolios and Specifications

13.3.3 Jiangxi Haoran Bio-Pharma Urokinase Sales, Revenue, Price and Gross

Margin (2021-2026)

13.3.4 Jiangxi Haoran Bio-Pharma Main Business Overview

13.3.5 Jiangxi Haoran Bio-Pharma Latest Developments

13.4 Jiangsu Aidea Pharmaceutical

13.4.1 Jiangsu Aidea Pharmaceutical Company Information

13.4.2 Jiangsu Aidea Pharmaceutical Urokinase Product Portfolios and Specifications

13.4.3 Jiangsu Aidea Pharmaceutical Urokinase Sales, Revenue, Price and Gross

Margin (2021-2026)

13.4.4 Jiangsu Aidea Pharmaceutical Main Business Overview

13.4.5 Jiangsu Aidea Pharmaceutical Latest Developments

13.5 Techpool

13.5.1 Techpool Company Information

13.5.2 Techpool Urokinase Product Portfolios and Specifications

13.5.3 Techpool Urokinase Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Techpool Main Business Overview

13.5.5 Techpool Latest Developments

13.6 Microbic Biosystems

13.6.1 Microbic Biosystems Company Information

13.6.2 Microbic Biosystems Urokinase Product Portfolios and Specifications

13.6.3 Microbic Biosystems Urokinase Sales, Revenue, Price and Gross Margin

(2021-2026)

13.6.4 Microbic Biosystems Main Business Overview

13.6.5 Microbic Biosystems Latest Developments

13.7 LIVZON

13.7.1 LIVZON Company Information

13.7.2 LIVZON Urokinase Product Portfolios and Specifications

13.7.3 LIVZON Urokinase Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 LIVZON Main Business Overview

13.7.5 LIVZON Latest Developments

13.8 Wuhan Humanwell Pharma

13.8.1 Wuhan Humanwell Pharma Company Information

13.8.2 Wuhan Humanwell Pharma Urokinase Product Portfolios and Specifications

13.8.3 Wuhan Humanwell Pharma Urokinase Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Wuhan Humanwell Pharma Main Business Overview

13.8.5 Wuhan Humanwell Pharma Latest Developments

13.9 Tianjin Biochem Pharma

13.9.1 Tianjin Biochem Pharma Company Information

13.9.2 Tianjin Biochem Pharma Urokinase Product Portfolios and Specifications

13.9.3 Tianjin Biochem Pharma Urokinase Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Tianjin Biochem Pharma Main Business Overview

13.9.5 Tianjin Biochem Pharma Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Urokinase Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Urokinase Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Urokinase Powder

Table 4. Major Players of Urokinase Solution

Table 5. Global Urokinase Sales by Type (2021-2026) & (BIU)

Table 6. Global Urokinase Sales Market Share by Type (2021-2026)

Table 7. Global Urokinase Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Urokinase Revenue Market Share by Type (2021-2026)

Table 9. Global Urokinase Sale Price by Type (2021-2026) & (US\$/MIU)

Table 10. Major Players of Pulmonary Embolism Thrombolysis

Table 11. Major Players of Deep Vein Thrombosis

Table 12. Major Players of Peripheral Arterial Occlusion Thrombolysis

Table 13. Major Players of Catheter / Cannula Occlusion Clearance

Table 14. Major Players of Others

Table 15. Global Urokinase Sales by Clinical Use (2021-2026) & (BIU)

Table 16. Global Urokinase Sales Market Share by Clinical Use (2021-2026)

Table 17. Global Urokinase Revenue by Clinical Use (2021-2026) & (\$ million)

Table 18. Global Urokinase Revenue Market Share by Clinical Use (2021-2026)

Table 19. Global Urokinase Sale Price by Clinical Use (2021-2026) & (US\$/MIU)

Table 20. Major Players of Systemic Infusion

Table 21. Major Players of Catheter-directed Thrombolysis (CDT)

Table 22. Major Players of Intracatheter Dwell / Lock Technique

Table 23. Global Urokinase Sales by Administration Approach (2021-2026) & (BIU)

Table 24. Global Urokinase Sales Market Share by Administration Approach (2021-2026)

Table 25. Global Urokinase Revenue by Administration Approach (2021-2026) & (\$ million)

Table 26. Global Urokinase Revenue Market Share by Administration Approach (2021-2026)

Table 27. Global Urokinase Sale Price by Administration Approach (2021-2026) & (US\$/MIU)

Table 28. Major Players of Standard Clinical Grade

Table 29. Major Players of High-purity / Low-impurity Grade

Table 30. Major Players of Low Endotoxin / Low Bioburden Specifications
Table 31. Global Urokinase Sales by Purity (2021-2026) & (BIU)
Table 32. Global Urokinase Sales Market Share by Purity (2021-2026)
Table 33. Global Urokinase Revenue by Purity (2021-2026) & (\$ million)
Table 34. Global Urokinase Revenue Market Share by Purity (2021-2026)
Table 35. Global Urokinase Sale Price by Purity (2021-2026) & (US\$/MIU)
Table 36. Global Urokinase Sale by Application (2021-2026) & (BIU)
Table 37. Global Urokinase Sale Market Share by Application (2021-2026)
Table 38. Global Urokinase Revenue by Application (2021-2026) & (\$ million)
Table 39. Global Urokinase Revenue Market Share by Application (2021-2026)
Table 40. Global Urokinase Sale Price by Application (2021-2026) & (US\$/MIU)
Table 41. Global Urokinase Sales by Company (2021-2026) & (BIU)
Table 42. Global Urokinase Sales Market Share by Company (2021-2026)
Table 43. Global Urokinase Revenue by Company (2021-2026) & (\$ millions)
Table 44. Global Urokinase Revenue Market Share by Company (2021-2026)
Table 45. Global Urokinase Sale Price by Company (2021-2026) & (US\$/MIU)
Table 46. Key Manufacturers Urokinase Producing Area Distribution and Sales Area
Table 47. Players Urokinase Products Offered
Table 48. Urokinase Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 49. New Products and Potential Entrants
Table 50. Market M&A Activity & Strategy
Table 51. Global Urokinase Sales by Geographic Region (2021-2026) & (BIU)
Table 52. Global Urokinase Sales Market Share Geographic Region (2021-2026)
Table 53. Global Urokinase Revenue by Geographic Region (2021-2026) & (\$ millions)
Table 54. Global Urokinase Revenue Market Share by Geographic Region (2021-2026)
Table 55. Global Urokinase Sales by Country/Region (2021-2026) & (BIU)
Table 56. Global Urokinase Sales Market Share by Country/Region (2021-2026)
Table 57. Global Urokinase Revenue by Country/Region (2021-2026) & (\$ millions)
Table 58. Global Urokinase Revenue Market Share by Country/Region (2021-2026)
Table 59. Americas Urokinase Sales by Country (2021-2026) & (BIU)
Table 60. Americas Urokinase Sales Market Share by Country (2021-2026)
Table 61. Americas Urokinase Revenue by Country (2021-2026) & (\$ millions)
Table 62. Americas Urokinase Sales by Type (2021-2026) & (BIU)
Table 63. Americas Urokinase Sales by Application (2021-2026) & (BIU)
Table 64. APAC Urokinase Sales by Region (2021-2026) & (BIU)
Table 65. APAC Urokinase Sales Market Share by Region (2021-2026)
Table 66. APAC Urokinase Revenue by Region (2021-2026) & (\$ millions)
Table 67. APAC Urokinase Sales by Type (2021-2026) & (BIU)
Table 68. APAC Urokinase Sales by Application (2021-2026) & (BIU)

Table 69. Europe Urokinase Sales by Country (2021-2026) & (BIU)
Table 70. Europe Urokinase Revenue by Country (2021-2026) & (\$ millions)
Table 71. Europe Urokinase Sales by Type (2021-2026) & (BIU)
Table 72. Europe Urokinase Sales by Application (2021-2026) & (BIU)
Table 73. Middle East & Africa Urokinase Sales by Country (2021-2026) & (BIU)
Table 74. Middle East & Africa Urokinase Revenue Market Share by Country (2021-2026)
Table 75. Middle East & Africa Urokinase Sales by Type (2021-2026) & (BIU)
Table 76. Middle East & Africa Urokinase Sales by Application (2021-2026) & (BIU)
Table 77. Key Market Drivers & Growth Opportunities of Urokinase
Table 78. Key Market Challenges & Risks of Urokinase
Table 79. Key Industry Trends of Urokinase
Table 80. Urokinase Raw Material
Table 81. Key Suppliers of Raw Materials
Table 82. Urokinase Distributors List
Table 83. Urokinase Customer List
Table 84. Global Urokinase Sales Forecast by Region (2027-2032) & (BIU)
Table 85. Global Urokinase Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 86. Americas Urokinase Sales Forecast by Country (2027-2032) & (BIU)
Table 87. Americas Urokinase Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 88. APAC Urokinase Sales Forecast by Region (2027-2032) & (BIU)
Table 89. APAC Urokinase Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 90. Europe Urokinase Sales Forecast by Country (2027-2032) & (BIU)
Table 91. Europe Urokinase Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 92. Middle East & Africa Urokinase Sales Forecast by Country (2027-2032) & (BIU)
Table 93. Middle East & Africa Urokinase Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 94. Global Urokinase Sales Forecast by Type (2027-2032) & (BIU)
Table 95. Global Urokinase Revenue Forecast by Type (2027-2032) & (\$ millions)
Table 96. Global Urokinase Sales Forecast by Application (2027-2032) & (BIU)
Table 97. Global Urokinase Revenue Forecast by Application (2027-2032) & (\$ millions)
Table 98. Syner-Med Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors
Table 99. Syner-Med Urokinase Product Portfolios and Specifications
Table 100. Syner-Med Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 101. Syner-Med Main Business

Table 102. Syner-Med Latest Developments

Table 103. Wanhua Biochem Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 104. Wanhua Biochem Urokinase Product Portfolios and Specifications

Table 105. Wanhua Biochem Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 106. Wanhua Biochem Main Business

Table 107. Wanhua Biochem Latest Developments

Table 108. Jiangxi Haoran Bio-Pharma Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 109. Jiangxi Haoran Bio-Pharma Urokinase Product Portfolios and Specifications

Table 110. Jiangxi Haoran Bio-Pharma Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 111. Jiangxi Haoran Bio-Pharma Main Business

Table 112. Jiangxi Haoran Bio-Pharma Latest Developments

Table 113. Jiangsu Aidea Pharmaceutical Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 114. Jiangsu Aidea Pharmaceutical Urokinase Product Portfolios and Specifications

Table 115. Jiangsu Aidea Pharmaceutical Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 116. Jiangsu Aidea Pharmaceutical Main Business

Table 117. Jiangsu Aidea Pharmaceutical Latest Developments

Table 118. Techpool Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 119. Techpool Urokinase Product Portfolios and Specifications

Table 120. Techpool Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 121. Techpool Main Business

Table 122. Techpool Latest Developments

Table 123. Microbic Biosystems Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 124. Microbic Biosystems Urokinase Product Portfolios and Specifications

Table 125. Microbic Biosystems Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 126. Microbic Biosystems Main Business

Table 127. Microbic Biosystems Latest Developments

Table 128. LIVZON Basic Information, Urokinase Manufacturing Base, Sales Area and

Its Competitors

Table 129. LIVZON Urokinase Product Portfolios and Specifications

Table 130. LIVZON Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 131. LIVZON Main Business

Table 132. LIVZON Latest Developments

Table 133. Wuhan Humanwell Pharma Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 134. Wuhan Humanwell Pharma Urokinase Product Portfolios and Specifications

Table 135. Wuhan Humanwell Pharma Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 136. Wuhan Humanwell Pharma Main Business

Table 137. Wuhan Humanwell Pharma Latest Developments

Table 138. Tianjin Biochem Pharma Basic Information, Urokinase Manufacturing Base, Sales Area and Its Competitors

Table 139. Tianjin Biochem Pharma Urokinase Product Portfolios and Specifications

Table 140. Tianjin Biochem Pharma Urokinase Sales (BIU), Revenue (\$ Million), Price (US\$/MIU) and Gross Margin (2021-2026)

Table 141. Tianjin Biochem Pharma Main Business

Table 142. Tianjin Biochem Pharma Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Urokinase
- Figure 2. Urokinase Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Urokinase Sales Growth Rate 2021-2032 (BIU)
- Figure 7. Global Urokinase Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Urokinase Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Urokinase Sales Market Share by Country/Region (2025)
- Figure 10. Urokinase Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Urokinase Powder
- Figure 12. Product Picture of Urokinase Solution
- Figure 13. Global Urokinase Sales Market Share by Type in 2026
- Figure 14. Global Urokinase Revenue Market Share by Type (2021-2026)
- Figure 15. Product Picture of Pulmonary Embolism Thrombolysis
- Figure 16. Product Picture of Deep Vein Thrombosis
- Figure 17. Product Picture of Peripheral Arterial Occlusion Thrombolysis
- Figure 18. Product Picture of Catheter / Cannula Occlusion Clearance
- Figure 19. Product Picture of Others
- Figure 20. Global Urokinase Sales Market Share by Clinical Use in 2026
- Figure 21. Global Urokinase Revenue Market Share by Clinical Use (2021-2026)
- Figure 22. Product Picture of Systemic Infusion
- Figure 23. Product Picture of Catheter-directed Thrombolysis (CDT)
- Figure 24. Product Picture of Intracatheter Dwell / Lock Technique
- Figure 25. Global Urokinase Sales Market Share by Administration Approach in 2026
- Figure 26. Global Urokinase Revenue Market Share by Administration Approach (2021-2026)
- Figure 27. Product Picture of Standard Clinical Grade
- Figure 28. Product Picture of High-purity / Low-impurity Grade
- Figure 29. Product Picture of Low Endotoxin / Low Bioburden Specifications
- Figure 30. Global Urokinase Sales Market Share by Purity in 2026
- Figure 31. Global Urokinase Revenue Market Share by Purity (2021-2026)
- Figure 32. Urokinase Consumed in Hospital
- Figure 33. Global Urokinase Market: Hospital (2021-2026) & (BIU)
- Figure 34. Urokinase Consumed in Clinic

- Figure 35. Global Urokinase Market: Clinic (2021-2026) & (BIU)
- Figure 36. Urokinase Consumed in Others
- Figure 37. Global Urokinase Market: Others (2021-2026) & (BIU)
- Figure 38. Global Urokinase Sale Market Share by Application (2025)
- Figure 39. Global Urokinase Revenue Market Share by Application in 2026
- Figure 40. Urokinase Sales by Company in 2026 (BIU)
- Figure 41. Global Urokinase Sales Market Share by Company in 2026
- Figure 42. Urokinase Revenue by Company in 2026 (\$ millions)
- Figure 43. Global Urokinase Revenue Market Share by Company in 2026
- Figure 44. Global Urokinase Sales Market Share by Geographic Region (2021-2026)
- Figure 45. Global Urokinase Revenue Market Share by Geographic Region in 2026
- Figure 46. Americas Urokinase Sales 2021-2026 (BIU)
- Figure 47. Americas Urokinase Revenue 2021-2026 (\$ millions)
- Figure 48. APAC Urokinase Sales 2021-2026 (BIU)
- Figure 49. APAC Urokinase Revenue 2021-2026 (\$ millions)
- Figure 50. Europe Urokinase Sales 2021-2026 (BIU)
- Figure 51. Europe Urokinase Revenue 2021-2026 (\$ millions)
- Figure 52. Middle East & Africa Urokinase Sales 2021-2026 (BIU)
- Figure 53. Middle East & Africa Urokinase Revenue 2021-2026 (\$ millions)
- Figure 54. Americas Urokinase Sales Market Share by Country in 2026
- Figure 55. Americas Urokinase Revenue Market Share by Country (2021-2026)
- Figure 56. Americas Urokinase Sales Market Share by Type (2021-2026)
- Figure 57. Americas Urokinase Sales Market Share by Application (2021-2026)
- Figure 58. United States Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 59. Canada Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 60. Mexico Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 61. Brazil Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 62. APAC Urokinase Sales Market Share by Region in 2026
- Figure 63. APAC Urokinase Revenue Market Share by Region (2021-2026)
- Figure 64. APAC Urokinase Sales Market Share by Type (2021-2026)
- Figure 65. APAC Urokinase Sales Market Share by Application (2021-2026)
- Figure 66. China Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 67. Japan Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 68. South Korea Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 69. Southeast Asia Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 70. India Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 71. Australia Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 72. China Taiwan Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 73. Europe Urokinase Sales Market Share by Country in 2026

- Figure 74. Europe Urokinase Revenue Market Share by Country (2021-2026)
- Figure 75. Europe Urokinase Sales Market Share by Type (2021-2026)
- Figure 76. Europe Urokinase Sales Market Share by Application (2021-2026)
- Figure 77. Germany Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 78. France Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 79. UK Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 80. Italy Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 81. Russia Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 82. Middle East & Africa Urokinase Sales Market Share by Country (2021-2026)
- Figure 83. Middle East & Africa Urokinase Sales Market Share by Type (2021-2026)
- Figure 84. Middle East & Africa Urokinase Sales Market Share by Application (2021-2026)
- Figure 85. Egypt Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 86. South Africa Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 87. Israel Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 88. Turkey Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 89. GCC Countries Urokinase Revenue Growth 2021-2026 (\$ millions)
- Figure 90. Manufacturing Cost Structure Analysis of Urokinase in 2026
- Figure 91. Manufacturing Process Analysis of Urokinase
- Figure 92. Industry Chain Structure of Urokinase
- Figure 93. Channels of Distribution
- Figure 94. Global Urokinase Sales Market Forecast by Region (2027-2032)
- Figure 95. Global Urokinase Revenue Market Share Forecast by Region (2027-2032)
- Figure 96. Global Urokinase Sales Market Share Forecast by Type (2027-2032)
- Figure 97. Global Urokinase Revenue Market Share Forecast by Type (2027-2032)
- Figure 98. Global Urokinase Sales Market Share Forecast by Application (2027-2032)
- Figure 99. Global Urokinase Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Urokinase Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GA3E41A3642EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA3E41A3642EN.html>